- Home
- CSTL vs BGY Comparison
CSTL vs BGY Comparison
Compare CSTL & BGY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSTL
- BGY
- Stock Information
- Founded
- CSTL 2007
- BGY 2007
- Country
- CSTL United States
- BGY United States
- Employees
- CSTL 784
- BGY N/A
- Industry
- CSTL Medical Specialities
- BGY Trusts Except Educational Religious and Charitable
- Sector
- CSTL Health Care
- BGY Finance
- Exchange
- CSTL Nasdaq
- BGY Nasdaq
- Market Cap
- CSTL 456.2M
- BGY 487.0M
- IPO Year
- CSTL 2019
- BGY N/A
- Fundamental
- Price
- CSTL $15.95
- BGY $5.81
- Analyst Decision
- CSTL Strong Buy
- BGY
- Analyst Count
- CSTL 6
- BGY 0
- Target Price
- CSTL $37.67
- BGY N/A
- AVG Volume (30 Days)
- CSTL 527.3K
- BGY 208.4K
- Earning Date
- CSTL 05-05-2025
- BGY 01-01-0001
- Dividend Yield
- CSTL N/A
- BGY 7.41%
- EPS Growth
- CSTL N/A
- BGY N/A
- EPS
- CSTL N/A
- BGY N/A
- Revenue
- CSTL $347,083,000.00
- BGY N/A
- Revenue This Year
- CSTL N/A
- BGY N/A
- Revenue Next Year
- CSTL $1.80
- BGY N/A
- P/E Ratio
- CSTL N/A
- BGY N/A
- Revenue Growth
- CSTL 38.43
- BGY N/A
- 52 Week Low
- CSTL $15.45
- BGY $4.68
- 52 Week High
- CSTL $35.84
- BGY $5.66
- Technical
- Relative Strength Index (RSI)
- CSTL 33.63
- BGY 59.56
- Support Level
- CSTL $15.45
- BGY $5.78
- Resistance Level
- CSTL $16.43
- BGY $5.94
- Average True Range (ATR)
- CSTL 0.59
- BGY 0.08
- MACD
- CSTL 0.04
- BGY 0.00
- Stochastic Oscillator
- CSTL 15.93
- BGY 53.33
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.
About BGY Blackrock Enhanced International Dividend Trust
Blackrock Enhanced International Dividend Trust has an investment objective to provide current income and current gains, with a secondary objective of long-term capital appreciation. The Trust seeks to achieve its objectives by investing in equity securities of companies engaged in the energy and natural resources business and equity derivatives with exposure to the energy and natural resources industry.